Rare disease biotech Rallybio sets terms for $81 million IPO, Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, announced terms for its IPO on Thursday.The New Haven, CT-based company plans to raise $81 million by offering 5.8 million shares at a price range of $13 to $15. At the midpoint of the proposed range,,

Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, announced terms for its IPO on Thursday.The New Haven, CT-based company plans to raise $81 million by offering 5.8 million shares at a price range of $13 to $15. At the midpoint of the proposed range,

, , Renaissance Capital, {authorlink}, https://www.nasdaq.com/articles/rare-disease-biotech-rallybio-sets-terms-for-%2481-million-ipo-2021-07-22, https://www.nasdaq.com/feed/rssoutbound?category=IPOs, IPOs Feed,

This feed is responsible for generating the rss feed related to the topic ipos

, , IPO Calendar, 45, July 22, 2021, 10:04 pm

By A Silva

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.